World
CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2024 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
AIDS Vaccine Advocacy Coalition calls for Viread trials to continue
Although worldwide clinical trials of the anti-HIV drug Viread are drawing criticism from AIDS activists, the AIDS Vaccine Advocacy Coalition on Thursday issued a report that calls for the studies to continue, as the drug is still a possible way to prevent HIV infections. The report, titled "Will a Pill a Day Prevent HIV? Anticipating the Results of the Tenofovir PREP Trials," examines the issues and ethical concerns raised by some activists, particularly whether sex workers and injection-drug users in developing countries participating in the trials are being adequately counseled on safer sex, and whether those who become infected during the study should be given free lifetime supplies of antiretroviral drugs. AVAC says these issues can be adequately addressed by trial organizers and funders, and that the studies should continue with more concerted coordination and advance planning to accelerate data evaluation.
"The concerns raised about the trials are serious, and there is a need for thorough and unbiased investigation," said Mitchell Warren, AVAC executive director, in a press statement. "But all of the concerns raised are solvable. AVAC calls on researchers, communities, and advocates to work together to ensure that ethical concerns are addressed, solutions are found, and the trials go forward."
The studies, under way among sexually active gay men in the United States, female sex workers in Africa, and injection-drug users in Thailand, aim to determine whether daily doses of Viread are effective in preventing HIV infections that are transmitted through sexual contact or needle sharing. The AVAC report says that the World Health Organization, the Joint United Nations Programme on HIV/AIDS, the trial sponsors, and other organizations should work together to ensure that research and trials are coordinated and progress in an accelerated fashion--and that additional research is carried out in an expedited fashion--to ensure that it is known as soon as possible if Viread is a safe and effective HIV prevention intervention.
"We need as many HIV prevention tools as possible, so research on vaccines, microbicides, and other potential interventions must also be accelerated whether or not Viread proves appropriate for preexposure prophylaxis," Warren said.
The AVAC report is available online at www.avac.org and in print by sending a request via e-mail to avac@avac.org.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Meet all 37 of the queer women in this season's WNBA
April 17 2024 11:24 AM
Here are the 15 gayest travel destinations in the world: report
March 26 2024 9:23 AM
21+ steamy photos of Scotland’s finest gay men in Elska Glasgow
February 01 2024 10:07 PM
More Than 50 of Our Favorite LGBTQ+ Moms
May 12 2024 11:44 AM
Conjoined twins Lori Schappell and trans man George Schappell dead at 62
April 27 2024 6:13 PM
Latest Stories
Kamala Harris rides wave of Democratic energy at kickoff event in Wisconsin
July 23 2024 3:36 PM
'Devastated:' A six-week abortion ban will go into effect in Iowa next week
July 23 2024 2:28 PM
Four hours, 44,000 Black women, and one Zoom call
July 23 2024 2:17 PM
Record 1.2 million people show out for Cologne’s Pride parade
July 23 2024 10:51 AM
Here's how far-right activist Leonard Leo helped fund Bud Light boycott
July 23 2024 10:27 AM
Elon Musk’s comments about his trans daughter prove why she doesn’t speak to him
July 23 2024 9:16 AM
Nancy Pelosi endorses Kamala Harris for president
July 22 2024 4:07 PM
Charli XCX declares Kamala Harris IS brat & our next President's campaign agrees
July 22 2024 3:08 PM